Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Sep;10(9):909-15.
doi: 10.1038/nm1100.

Cancer immunotherapy: moving beyond current vaccines

Steven A Rosenberg  1 , James C Yang, Nicholas P Restifo
Affiliations
Comparative Study

Cancer immunotherapy: moving beyond current vaccines

Steven A Rosenberg et al. Nat Med. 2004 Sep.

Abstract

Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

PubMed Disclaimer

Comment in

  • Cancer vaccines: pessimism in check.
    Mocellin S, Mandruzzato S, Bronte V, Marincola FM. Mocellin S, et al. Nat Med. 2004 Dec;10(12):1278-9; author reply 1279-80. doi: 10.1038/nm1204-1278. Nat Med. 2004. PMID: 15580242 No abstract available.
  • Cancer vaccines: pessimism in check.
    Timmerman JM, Levy R. Timmerman JM, et al. Nat Med. 2004 Dec;10(12):1279; author reply 1279-80. doi: 10.1038/nm1204-1279a. Nat Med. 2004. PMID: 15682512 No abstract available.

Similar articles

  • Cancer vaccines: pessimism in check.
    Mocellin S, Mandruzzato S, Bronte V, Marincola FM. Mocellin S, et al. Nat Med. 2004 Dec;10(12):1278-9; author reply 1279-80. doi: 10.1038/nm1204-1278. Nat Med. 2004. PMID: 15580242 No abstract available.
  • Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q, Zhang CD, Wu XH. Song Q, et al. Immunol Lett. 2018 Apr;196:11-21. doi: 10.1016/j.imlet.2018.01.011. Epub 2018 Feb 4. Immunol Lett. 2018. PMID: 29407608 Review.
  • Immunotherapy of metastasis.
    Dallal RM, Lotze MT. Dallal RM, et al. Surg Oncol Clin N Am. 2001 Apr;10(2):433-47, xi. Surg Oncol Clin N Am. 2001. PMID: 11382596 Review.
  • Cancer vaccines: pessimism in check.
    Timmerman JM, Levy R. Timmerman JM, et al. Nat Med. 2004 Dec;10(12):1279; author reply 1279-80. doi: 10.1038/nm1204-1279a. Nat Med. 2004. PMID: 15682512 No abstract available.
  • Cancer vaccines. Any future?
    Myc LA, Gamian A, Myc A. Myc LA, et al. Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):249-59. doi: 10.1007/s00005-011-0129-y. Epub 2011 Jun 5. Arch Immunol Ther Exp (Warsz). 2011. PMID: 21644030 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–384. - PubMed
    1. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21:876–886. - PubMed
    1. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21:2415–2432. - PubMed
    1. Overwijk WW, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569–580. - PMC - PubMed
    1. Dudley ME, et al. Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes. Science. 2002;298:850–854. - PMC - PubMed

Publication types